 BATON ROUGE, La., and BANNOCKBURN, Ill., Jan. 05, 2021 GLOBE NEWSWIRE -- Amedisys, Inc. NASDAQ: AMED, a leading provider of home health, hospice and personal care, and Option Care Health Inc. NASDAQ: OPCH, the nations largest independent home and alternate site infusion services provider, are collaborating on providing COVID antibody infusion therapy within skilled nursing and assisted living facilities, collectively referred to as long term care facilities. The U.S Food and Drug Administration FDA has issued Emergency Use Authorizations EUAs to both Eli Lilly and Regeneron for their investigational neutralizing antibody therapies to treat mild to moderate COVID-19 in adults and pediatrics who are at high risk for progressing to severe COVID-19 symptoms or hospitalization. 